


### REMARKS

Applicants respond to the Examiner's request for a species election and respectfully request entry and consideration of the present amendment to claims 5, 21, and 57, which have been amended to include a tumor necrosis factor-alpha (TNF- $\alpha$ ) receptor II agonist among the list of TNF-alpha agonists and TNF-alpha inducing substances, and claims 30, 45, 53, and 59, which have been amended to exclude claim dependencies from withdrawn claims. Support for the amendment to claims 5, 21, and 57 is found in the application at, e.g., page 48, lines 18-19. No new matter is added by the amendment.

Enclosed is a petition to extend the period for replying for three months, to and including December 28, 2006, and a check for the fee required under 37 C.F.R. § 1.17(a). If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: Aug. 21, 2006

  
\_\_\_\_\_  
Paul T. Clark  
Reg. No. 30,162

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045